Summary

The global gut microbiome testing market is projected to reach USD 2,104.4 million by 2036, expanding at a CAGR of 7.09% during the forecast period from 2025 to 2036. Rising awareness regarding digestive health, personalized nutrition, and preventive healthcare is expected to support market growth worldwide.

Rising Demand for Personalized Nutrition
The increasing popularity of getting one's gut health tested to personalize nutrition is turning out to be a significant factor propelling the global gut microbiome testing industry. More people are going for microbiome testing to obtain individualized dietary plans that can help them improve digestion, metabolism, and overall health based on one's unique gut microbial composition.

Market Segmentations Key Insights
By Product & Services
- Instruments: Advanced tools enabling accurate microbiome sample analysis.
- Consumables and Services: Essential testing supplies and sequencing support services.
By Application
- 16S rRNA Sequencing: Widely used for bacterial community identification studies.
- Shotgun Metagenomics: Provides comprehensive microbial genomic profiling capabilities.
- Meta transcriptomics: Examines active microbial gene expression patterns.
- Next Generation Sequencing: Enables high-throughput and precise microbiome sequencing.
- Others: Includes emerging and specialized microbiome testing techniques.
By Sample Type
- Stool (Faecal) Samples: Most preferred sample type for gut analysis.
- Saliva Samples: Used for convenient non-invasive microbial assessments.
- Others: Includes skin, urine, and tissue-based samples.
By Indication
- Ulcerative Colitis: Supports monitoring of gut inflammation-related conditions.
- Irritable Bowel Syndrome (IBS): Helps assess microbiome imbalance in IBS patients.
- Chronic Diarrhoea & Constipation: Identifies microbial factors affecting digestive irregularities.
- Type-2 Diabetes: Links gut bacteria with metabolic health conditions.
- Obesity: Evaluates microbiome influence on weight management processes.
- Rheumatoid Arthritis: Explores gut microbiome connections with autoimmune disorders.
- Multiple Sclerosis: Studies microbial impact on neurological disease progression.
- Parkinson’s Disease: Investigates gut-brain interactions in Parkinson’s development.
- Alzheimer’s Disease: Examines microbiome role in cognitive health decline.
- Others: Covers additional gastrointestinal and chronic health disorders.
By End User
- Hospitals: Utilize microbiome testing for clinical patient management.
- Diagnostic Laboratories: Conduct specialized microbial testing and sequencing procedures.
- Others: Includes research institutes and wellness service providers.

North America and Europe are leading the gut microbiome testing market, mainly because of their well-established biotechnology infrastructure, higher awareness regarding gut health, and greater usage of precision diagnostics. On the other hand, Asia-Pacific is becoming the region with the fastest developing market, and both South America and the Middle East & Africa have steady growth due to factors such as the incidence of metabolic disorders and more healthcare spending.

Advanced Postbiotic Innovation
October 2025 saw the launch of Phorum, a next-generation postbiotic ingredient created from heat-treated bacterial and fungal strains that help the immune system, by BIOHM Health, Inc. This new product reflects the company's commitment to microbiome solutions that are scientifically-advanced and that provide stable bioactive effects without depending on live microorganisms.

Integrated Healthcare Ecosystems
Strategic collaborations amongst diagnostic companies, healthcare providers, and wellness platforms that use digital technology are greatly enhancing the gut microbiome testing market. These alliances are leading to the formation of integrated healthcare ecosystems that combine microbiome analysis with personalized nutrition, supplements, and telehealth services to deliver higher patient engagement.

Key Report Attributes
- Market Size 2036: USD 2,104.4 Million
- CAGR (2025-2036): 7.09%
- Base Year: 2024
- Market Forecast Period: 2025-2036

Industry Segmentations Growth
- By Product & Services: Instruments - 5.80%, Consumables - 6.70%.
- By Application: 16S rRNA Sequencing - 6.32%, Shotgun Metagenomics - 8.50%.
- By Sample Type: Stool (Faecal) Samples - 6.94%, Saliva Samples - 9.32%.
- By Indication: Ulcerative Colitis - 4.58%, Irritable Bowel Syndrome (IBS) - 4.15%.
- By End User: Hospitals - 7.82%, Diagnostic Laboratories - 6.84%.

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1 EXECUTIVE SUMMARY ........ 19
2 MARKET INTRODUCTION ..... 21
2.1 DEFINITION ....... 21
2.2 SCOPE OF THE STUDY ............... 21
2.3 RESEARCH OBJECTIVE ........ 21
2.4 MARKET STRUCTURE ..... 22
3 RESEARCH METHODOLOGY ........... 23
3.1 OVERVIEW ........... 23
3.2 DATA FLOW ......... 25
3.2.1 DATA MINING PROCESS .... 25
3.3 PURCHASED DATABASE: ..... 26
3.4 SECONDARY SOURCES: ....... 27
3.4.1 SECONDARY RESEARCH DATA FLOW: ........ 28
3.5 PRIMARY RESEARCH: ......... 29
3.5.1 PRIMARY RESEARCH DATA FLOW: ............ 30
3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED ........ 31
3.5.3 PRIMARY RESEARCH: REGIONAL COVERAGE ......... 31
3.6 APPROACHES FOR MARKET SIZE ESTIMATION: .............. 32
3.6.1 REVENUE ANALYSIS APPROACH .... 32
3.7 DATA FORECASTING ............ 33
3.7.1 DATA FORECASTING TYPE ............. 33
3.8 DATA MODELING ............... 34
3.8.1 MICROECONOMIC FACTOR ANALYSIS: ....... 34
3.8.2 DATA MODELING: .............. 35
3.9 TEAMS AND ANALYST CONTRIBUTION ............. 37
4 MARKET DYNAMICS ............. 39
4.1 INTRODUCTION ...... 39
4.2 MARKET TRENDS AND GROWTH AFFECTING FACTORS ........ 40
4.3 DRIVERS .............. 41
4.3.1 RISING AWARENESS OF GUT HEALTH AND DISEASE LINKAGES ....... 41
4.3.2 GROWTH OF PERSONALIZED NUTRITION & PREVENTIVE HEALTH ............... 41
4.4 RESTRAINTS ......... 42
4.4.1 LIMITED CLINICAL VALIDATION & STANDARDIZATION ........ 42
4.4.2 DATA PRIVACY & INTEGRATION ISSUES ..... 43
4.5 OPPORTUNITY ....... 43
4.5.1 EXPANSION BEYOND GI DISORDERS ........... 43
4.5.2 PARTNERSHIPS & INTEGRATED HEALTH SOLUTIONS ......... 44
5 INDUSTRY TREND ANALYSIS .......... 45
5.1 REGULATORY ENVIRONMENT & COMPLIANCE .... 45
5.2 TECHNOLOGICAL TRENDS & INNOVATION ......... 46
5.3 PATIENT DEMOGRAPHICS & DISEASE BURDENS ........... 47
5.4 PRICING ANALYSIS & REIMBURSEMENT DYNAMICS ...... 48
5.5 MARKET ENTRY & EXIT BARRIERS ........ 48
5.6 PARTNERSHIPS & COLLABORATIONS .... 49
5.7 CONSUMER & HEALTHCARE PROVIDER PREFERENCES ..... 50
5.8 PESTLE ANALYSIS .............. 51
5.9 ’ F F ......... 52
5.9.1 THREAT OF NEW ENTRANTS .......... 52
5.9.2 BARGAINING POWER OF SUPPLIERS .......... 53
5.9.3 THREAT OF SUBSTITUTES ............. 53
5.9.4 BARGAINING POWER OF BUYERS ............... 53
5.9.5 INTENSITY OF RIVALRY ..... 53
6 GLOBAL GUT MICROBIOME TESTING MARKET, BY PRODUCT AND SERVICE ............. 55
6.1 OVERVIEW ........... 55
7 GLOBAL GUT MICROBIOME TESTING MARKET, BY APPLICATION ........ 58
7.1 OVERVIEW ........... 58
8 GLOBAL GUT MICROBIOME TESTING MARKET, BY SAMPLE TYPE ....... 61
8.1 OVERVIEW ........... 61
9 GLOBAL GUT MICROBIOME TESTING MARKET, BY INDICATION ........... 64
9.1 OVERVIEW ........... 64
10 GLOBAL GUT MICROBIOME TESTING MARKET, BY END USER ............. 68
10.1 OVERVIEW ........... 68
11 GLOBAL GUT MICROBIOME TESTING MARKET, BY REGION ...... 70
11.1 OVERVIEW ........... 70
11.2 NORTH AMERICA ............... 72
11.2.1 US ............ 77
11.2.2 CANADA ............... 80
11.3 EUROPE .............. 83
11.3.1 GERMANY ............. 88
11.3.2 UK ............ 91
11.3.3 FRANCE .... 94
11.3.4 ITALY ........ 97
11.3.5 SPAIN ....... 100
11.3.6 RUSSIA ..... 103
11.3.7 REST OF EUROPE ............... 106
11.4 ASIA PACIFIC ....... 109
11.4.1 CHINA ....... 115
11.4.2 JAPAN ...... 118
11.4.3 INDIA ........ 121
11.4.4 ITALY ........ 124
11.4.5 INDONESIA ........... 127
11.4.6 THAILAND ............. 130
11.4.7 REST OF ASIA PACIFIC ...... 133
11.5 SOUTH AMERICA ............... 136
11.5.1 BRAZIL ...... 141
11.5.2 MEXICO .... 144
11.5.3 ARGENTINA .......... 147
11.5.4 REST OF SOUTH AMERICA ............. 150
11.6 MIDDLE EAST & AFRICA ....... 153
11.6.1 GCC COUNTRIES ............... 158
11.6.2 SOUTH AFRICA ...... 161
11.6.3 REST OF SOUTH AMERICA ............. 164
12 COMPETITIVE LANDSCAPE ............. 168
12.1 INTRODUCTION ...... 168
12.2 MARKET SHARE ANALYSIS, 2024 ...... 169
12.3 COMPETITOR DASHBOARD .... 170
12.4 KEY DEVELOPMENTS & GROWTH STRATEGIES ............... 171
12.4.1 INDUSTRY KEY DEVELOPMENT ...... 171
13 COMPANY PROFILES ........... 173
13.1 VIOME, INC. ...... 173
13.1.1 COMPANY OVERVIEW ........ 173
13.1.2 PRODUCT OFFERED ........... 174
13.1.3 SWOT ANALYSIS ............... 175
13.1.4 KEY STRATEGY ...... 175
13.2 OMBRE ............... 177
13.2.1 COMPANY OVERVIEW ........ 177
13.2.2 PRODUCT OFFERED ........... 178
13.2.3 SWOT ANALYSIS ............... 178
13.3 BASECLEAR B.V. ........... 180
13.3.1 COMPANY OVERVIEW ........ 180
13.3.2 PRODUCT OFFERED ........... 181
13.3.3 SWOT ANALYSIS ............... 181
13.3.4 KEY STRATEGY ...... 182
13.4 ATLAS BIOLABS ............ 183
13.4.1 COMPANY OVERVIEW ........ 183
13.4.2 PRODUCT OFFERED ........... 184
13.4.3 SWOT ANALYSIS ............... 184
13.4.4 KEY STRATEGY ...... 185
13.5 MICROBA LIFE SCIENCES ........... 186
13.5.1 COMPANY OVERVIEW ....... 186
13.5.2 FINANCIAL ANALYSIS ........ 187
13.5.3 PRODUCT OFFERED ........... 188
13.5.4 SWOT ANALYSIS ............... 189
13.5.5 KEY STRATEGY ...... 189
13.6 GENOVA DIAGNOSTICS, LTD ...... 190
13.6.1 COMPANY OVERVIEW ........ 190
13.6.2 PRODUCT OFFERED ........... 191
13.6.3 SWOT ANALYSIS ............... 192
13.6.4 KEY STRATEGY ...... 193
13.7 SUN GENOMICS, INC. ..... 194
13.7.1 COMPANY OVERVIEW ........ 194
13.7.2 PRODUCT OFFERED ........... 195
13.7.3 SWOT ANALYSIS ............... 195
13.7.4 KEY STRATEGY ...... 196
13.8 BIOHM HEALTH, INC ......... 197
13.8.1 COMPANY OVERVIEW ........ 197
13.8.2 PRODUCT OFFERED ........... 198
13.8.3 SWOT ANALYSIS ............... 199
13.8.4 KEY STRATEGY ...... 200
13.9 ZYMO RESEARCH CORPORATION........ 201
13.9.1 COMPANY OVERVIEW ........ 201
13.9.2 PRODUCT OFFERED ........... 202
13.9.3 SWOT ANALYSIS ............... 202
13.9.4 KEY STRATEGY ...... 203
13.10 COSMOSID INC. .... 204
13.10.1 COMPANY OVERVIEW ....... 204
13.10.2 PRODUCT OFFERED ........... 205
13.10.3 SWOT ANALYSIS ............... 206
13.10.4 KEY STRATEGY ...... 206
14 DATA CITATIONS ....... 207

ページTOPに戻る

List of Tables/Graphs

LIST OF TABLES
TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT 36
TABLE 2 GLOBAL GUT MICROBIOME TESTING MARKET, BY PRODUCT AND SERVICE, 2019–2036 (USD MILLION) 56
TABLE 3 GLOBAL GUT MICROBIOME TESTING MARKET, BY APPLICATION, 2019–2036 (USD MILLION) 60
TABLE 4 GLOBAL GUT MICROBIOME TESTING MARKET, BY SAMPLE TYPE, 2019–2036 (USD MILLION) 62
TABLE 5 GLOBAL GUT MICROBIOME TESTING MARKET, BY INDICATION, 2019–2036 (USD MILLION) 67
TABLE 6 GLOBAL GUT MICROBIOME TESTING MARKET, BY END USER, 2019–2036 (USD MILLION) 69
TABLE 7 GLOBAL GUT MICROBIOME TESTINGS MARKET, BY REGION, 2019-2035 (USD MILLION) 70
TABLE 8 NORTH AMERICA GUT MICROBIOME TESTING MARKET, BY COUNTRY, 2019-2035 (USD MILLION) 73
TABLE 9 NORTH AMERICA: GUT MICROBIOME TESTING, BY PRODUCT & SERVICE, 2019–2036 (USD MILLION) 74
TABLE 10 NORTH AMERICA: GUT MICROBIOME TESTING, BY APPLICATION, 2019–2036 (USD MILLION) 74
TABLE 11 NORTH AMERICA: GUT MICROBIOME TESTING, BY SAMPLE TYPE, 2019–2036 (USD MILLION) 75
TABLE 12 NORTH AMERICA: GUT MICROBIOME TESTING, BY INDICATION, 2019–2036 (USD MILLION) 75
TABLE 13 NORTH AMERICA: GUT MICROBIOME TESTING, BY END USER, 2019–2036 (USD MILLION) 76
TABLE 14 U.S.: GUT MICROBIOME TESTING, BY PRODUCT & SERVICE, 2019–2036 (USD MILLION) 77
TABLE 15 U.S.: GUT MICROBIOME TESTING, BY APPLICATION, 2019–2036 (USD MILLION) 77
TABLE 16 U.S.: GUT MICROBIOME TESTING, BY SAMPLE TYPE, 2019–2036 (USD MILLION) 78
TABLE 17 U.S.: GUT MICROBIOME TESTING, BY INDICATION, 2019–2036 (USD MILLION) 78
TABLE 18 U.S.: GUT MICROBIOME TESTING, BY END USER, 2019–2036 (USD MILLION) 79
TABLE 19 CANADA: GUT MICROBIOME TESTING, BY PRODUCT & SERVICE, 2019–2036 (USD MILLION) 80
TABLE 20 CANADA: GUT MICROBIOME TESTING, BY APPLICATION, 2019–2036 (USD MILLION) 80
TABLE 21 CANADA: GUT MICROBIOME TESTING, BY SAMPLE TYPE, 2019–2036 (USD MILLION) 81
TABLE 22 CANADA: GUT MICROBIOME TESTING, BY INDICATION, 2019–2036 (USD MILLION) 81
TABLE 23 CANADA: GUT MICROBIOME TESTING, BY END USER, 2019–2036 (USD MILLION) 82
TABLE 24 EUROPE GUT MICROBIOME TESTING MARKET, BY COUNTRY, 2019-2035 (USD MILLION) 84
TABLE 25 EUROPE: GUT MICROBIOME TESTING, BY PRODUCT & SERVICE, 2019–2036 (USD MILLION) 85
TABLE 26 EUROPE: GUT MICROBIOME TESTING, BY APPLICATION, 2019–2036 (USD MILLION) 85
TABLE 27 EUROPE: GUT MICROBIOME TESTING, BY SAMPLE TYPE, 2019–2036 (USD MILLION) 86
TABLE 28 EUROPE: GUT MICROBIOME TESTING, BY INDICATION, 2019–2036 (USD MILLION) 86
TABLE 29 EUROPE: GUT MICROBIOME TESTING, BY END USER, 2019–2036 (USD MILLION) 87
TABLE 30 GERMANY: GUT MICROBIOME TESTING, BY PRODUCT & SERVICE, 2019–2036 (USD MILLION) 88
TABLE 31 GERMANY: GUT MICROBIOME TESTING, BY APPLICATION, 2019–2036 (USD MILLION) 88
TABLE 32 GERMANY: GUT MICROBIOME TESTING, BY SAMPLE TYPE, 2019–2036 (USD MILLION) 89
TABLE 33 GERMANY: GUT MICROBIOME TESTING, BY INDICATION, 2019–2036 (USD MILLION) 89
TABLE 34 GERMANY: GUT MICROBIOME TESTING, BY END USER, 2019–2036 (USD MILLION) 90
TABLE 35 UK: GUT MICROBIOME TESTING, BY PRODUCT & SERVICE, 2019–2036 (USD MILLION) 91
TABLE 36 UK: GUT MICROBIOME TESTING, BY APPLICATION, 2019–2036 (USD MILLION) 91
TABLE 37 UK: GUT MICROBIOME TESTING, BY SAMPLE TYPE, 2019–2036 (USD MILLION) 92
TABLE 38 UK: GUT MICROBIOME TESTING, BY INDICATION, 2019–2036 (USD MILLION) 92
TABLE 39 UK: GUT MICROBIOME TESTING, BY END USER, 2019–2036 (USD MILLION) 93
TABLE 40 FRANCE: GUT MICROBIOME TESTING, BY PRODUCT & SERVICE, 2019–2036 (USD MILLION) 94
TABLE 41 FRANCE: GUT MICROBIOME TESTING, BY APPLICATION, 2019–2036 (USD MILLION) 94
TABLE 42 FRANCE: GUT MICROBIOME TESTING, BY SAMPLE TYPE, 2019–2036 (USD MILLION) 95
TABLE 43 FRANCE: GUT MICROBIOME TESTING, BY INDICATION, 2019–2036 (USD MILLION) 95
TABLE 44 FRANCE: GUT MICROBIOME TESTING, BY END USER, 2019–2036 (USD MILLION) 96
TABLE 45 ITALY: GUT MICROBIOME TESTING, BY PRODUCT & SERVICE, 2019–2036 (USD MILLION) 97
TABLE 46 ITALY: GUT MICROBIOME TESTING, BY APPLICATION, 2019–2036 (USD MILLION) 97
TABLE 47 ITALY: GUT MICROBIOME TESTING, BY SAMPLE TYPE, 2019–2036 (USD MILLION) 98
TABLE 48 ITALY: GUT MICROBIOME TESTING, BY INDICATION, 2019–2036 (USD MILLION) 98
TABLE 49 ITALY: GUT MICROBIOME TESTING, BY END USER, 2019–2036 (USD MILLION) 99
TABLE 50 SPAIN: GUT MICROBIOME TESTING, BY PRODUCT & SERVICE, 2019–2036 (USD MILLION) 100
TABLE 51 SPAIN: GUT MICROBIOME TESTING, BY APPLICATION, 2019–2036 (USD MILLION) 100
TABLE 52 SPAIN: GUT MICROBIOME TESTING, BY SAMPLE TYPE, 2019–2036 (USD MILLION) 101
TABLE 53 SPAIN: GUT MICROBIOME TESTING, BY INDICATION, 2019–2036 (USD MILLION) 101
TABLE 54 SPAIN: GUT MICROBIOME TESTING, BY END USER, 2019–2036 (USD MILLION) 102
TABLE 55 RUSSIA: GUT MICROBIOME TESTING, BY PRODUCT & SERVICE, 2019–2036 (USD MILLION) 103
TABLE 56 RUSSIA: GUT MICROBIOME TESTING, BY APPLICATION, 2019–2036 (USD MILLION) 103
TABLE 57 RUSSIA: GUT MICROBIOME TESTING, BY SAMPLE TYPE, 2019–2036 (USD MILLION) 104
TABLE 58 RUSSIA: GUT MICROBIOME TESTING, BY INDICATION, 2019–2036 (USD MILLION) 104
TABLE 59 RUSSIA: GUT MICROBIOME TESTING, BY END USER, 2019–2036 (USD MILLION) 105
TABLE 60 REST OF EUROPE: GUT MICROBIOME TESTING, BY PRODUCT & SERVICE, 2019–2036 (USD MILLION) 106
TABLE 61 REST OF EUROPE: GUT MICROBIOME TESTING, BY APPLICATION, 2019–2036 (USD MILLION) 106
TABLE 62 REST OF EUROPE: GUT MICROBIOME TESTING, BY SAMPLE TYPE, 2019–2036 (USD MILLION) 107
TABLE 63 REST OF EUROPE: GUT MICROBIOME TESTING, BY INDICATION, 2019–2036 (USD MILLION) 107
TABLE 64 REST OF EUROPE: GUT MICROBIOME TESTING, BY END USER, 2019–2036 (USD MILLION) 108
TABLE 65 ASIA PACIFIC GUT MICROBIOME TESTING MARKET, BY COUNTRY, 2019-2036 (USD MILLION) 111
TABLE 66 ASIA PACIFIC: GUT MICROBIOME TESTING, BY PRODUCT & SERVICE, 2019–2036 (USD MILLION) 112
TABLE 67 ASIA PACIFIC: GUT MICROBIOME TESTING, BY APPLICATION, 2019–2036 (USD MILLION) 112
TABLE 68 ASIA PACIFIC: GUT MICROBIOME TESTING, BY SAMPLE TYPE, 2019–2036 (USD MILLION) 113
TABLE 69 ASIA PACIFIC: GUT MICROBIOME TESTING, BY INDICATION, 2019–2036 (USD MILLION) 113
TABLE 70 ASIA PACIFIC: GUT MICROBIOME TESTING, BY END USER, 2019–2036 (USD MILLION) 114
TABLE 71 CHINA: GUT MICROBIOME TESTING, BY PRODUCT & SERVICE, 2019–2036 (USD MILLION) 115
TABLE 72 CHINA: GUT MICROBIOME TESTING, BY APPLICATION, 2019–2036 (USD MILLION) 115
TABLE 73 CHINA: GUT MICROBIOME TESTING, BY SAMPLE TYPE, 2019–2036 (USD MILLION) 116
TABLE 74 CHINA: GUT MICROBIOME TESTING, BY INDICATION, 2019–2036 (USD MILLION) 116
TABLE 75 CHINA: GUT MICROBIOME TESTING, BY END USER, 2019–2036 (USD MILLION) 117
TABLE 76 JAPAN: GUT MICROBIOME TESTING, BY PRODUCT & SERVICE, 2019–2036 (USD MILLION) 118
TABLE 77 JAPAN: GUT MICROBIOME TESTING, BY APPLICATION, 2019–2036 (USD MILLION) 118
TABLE 78 JAPAN: GUT MICROBIOME TESTING, BY SAMPLE TYPE, 2019–2036 (USD MILLION) 119
TABLE 79 JAPAN: GUT MICROBIOME TESTING, BY INDICATION, 2019–2036 (USD MILLION) 119
TABLE 80 JAPAN: GUT MICROBIOME TESTING, BY END USER, 2019–2036 (USD MILLION) 120
TABLE 81 INDIA: GUT MICROBIOME TESTING, BY PRODUCT & SERVICE, 2019–2036 (USD MILLION) 121
TABLE 82 INDIA: GUT MICROBIOME TESTING, BY APPLICATION, 2019–2036 (USD MILLION) 121
TABLE 83 INDIA: GUT MICROBIOME TESTING, BY SAMPLE TYPE, 2019–2036 (USD MILLION) 122
TABLE 84 INDIA: GUT MICROBIOME TESTING, BY INDICATION, 2019–2036 (USD MILLION) 122
TABLE 85 INDIA: GUT MICROBIOME TESTING, BY END USER, 2019–2036 (USD MILLION) 123
TABLE 86 SOUTH KOREA: GUT MICROBIOME TESTING, BY PRODUCT & SERVICE, 2019–2036 (USD MILLION) 124
TABLE 87 SOUTH KOREA: GUT MICROBIOME TESTING, BY APPLICATION, 2019–2036 (USD MILLION) 124
TABLE 88 SOUTH KOREA: GUT MICROBIOME TESTING, BY SAMPLE TYPE, 2019–2036 (USD MILLION) 125
TABLE 89 SOUTH KOREA: GUT MICROBIOME TESTING, BY INDICATION, 2019–2036 (USD MILLION) 125
TABLE 90 SOUTH KOREA: GUT MICROBIOME TESTING, BY END USER, 2019–2036 (USD MILLION) 126
TABLE 91 INDONESIA: GUT MICROBIOME TESTING, BY PRODUCT & SERVICE, 2019–2036 (USD MILLION) 127
TABLE 92 INDONESIA: GUT MICROBIOME TESTING, BY APPLICATION, 2019–2036 (USD MILLION) 127
TABLE 93 INDONESIA: GUT MICROBIOME TESTING, BY SAMPLE TYPE, 2019–2036 (USD MILLION) 128
TABLE 94 INDONESIA: GUT MICROBIOME TESTING, BY INDICATION, 2019–2036 (USD MILLION) 128
TABLE 95 INDONESIA: GUT MICROBIOME TESTING, BY END USER, 2019–2036 (USD MILLION) 129
TABLE 96 THAILAND: GUT MICROBIOME TESTING, BY PRODUCT & SERVICE, 2019–2036 (USD MILLION) 130
TABLE 97 THAILAND: GUT MICROBIOME TESTING, BY APPLICATION, 2019–2036 (USD MILLION) 130
TABLE 98 THAILAND: GUT MICROBIOME TESTING, BY SAMPLE TYPE, 2019–2036 (USD MILLION) 131
TABLE 99 THAILAND: GUT MICROBIOME TESTING, BY INDICATION, 2019–2036 (USD MILLION) 131
TABLE 100 THAILAND: GUT MICROBIOME TESTING, BY END USER, 2019–2036 (USD MILLION) 132
TABLE 101 REST OF ASIA PACIFIC: GUT MICROBIOME TESTING, BY PRODUCT & SERVICE, 2019–2036 (USD MILLION) 133
TABLE 102 REST OF ASIA PACIFIC: GUT MICROBIOME TESTING, BY APPLICATION, 2019–2036 (USD MILLION) 133
TABLE 103 REST OF ASIA PACIFIC: GUT MICROBIOME TESTING, BY SAMPLE TYPE, 2019–2036 (USD MILLION) 134
TABLE 104 REST OF ASIA PACIFIC: GUT MICROBIOME TESTING, BY INDICATION, 2019–2036 (USD MILLION) 134
TABLE 105 REST OF ASIA PACIFIC: GUT MICROBIOME TESTING, BY END USER, 2019–2036 (USD MILLION) 135
TABLE 106 SOUTH AMERICA GUT MICROBIOME TESTING MARKET, BY COUNTRY, 2019-2035 (USD MILLION) 137
TABLE 107 SOUTH AMERICA: GUT MICROBIOME TESTING, BY PRODUCT & SERVICE, 2019–2036 (USD MILLION) 138
TABLE 108 SOUTH AMERICA: GUT MICROBIOME TESTING, BY APPLICATION, 2019–2036 (USD MILLION) 138
TABLE 109 SOUTH AMERICA: GUT MICROBIOME TESTING, BY SAMPLE TYPE, 2019–2036 (USD MILLION) 139
TABLE 110 SOUTH AMERICA: GUT MICROBIOME TESTING, BY INDICATION, 2019–2036 (USD MILLION) 139
TABLE 111 SOUTH AMERICA: GUT MICROBIOME TESTING, BY END USER, 2019–2036 (USD MILLION) 140
TABLE 112 BRAZIL: GUT MICROBIOME TESTING, BY PRODUCT & SERVICE, 2019–2036 (USD MILLION) 141
TABLE 113 BRAZIL: GUT MICROBIOME TESTING, BY APPLICATION, 2019–2036 (USD MILLION) 141
TABLE 114 BRAZIL: GUT MICROBIOME TESTING, BY SAMPLE TYPE, 2019–2036 (USD MILLION) 142
TABLE 115 BRAZIL: GUT MICROBIOME TESTING, BY INDICATION, 2019–2036 (USD MILLION) 142
TABLE 116 BRAZIL: GUT MICROBIOME TESTING, BY END USER, 2019–2036 (USD MILLION) 143
TABLE 117 MEXICO: GUT MICROBIOME TESTING, BY PRODUCT & SERVICE, 2019–2036 (USD MILLION) 144
TABLE 118 MEXICO: GUT MICROBIOME TESTING, BY APPLICATION, 2019–2036 (USD MILLION)
TABLE 119 MEXICO: GUT MICROBIOME TESTING, BY SAMPLE TYPE, 2019–2036 (USD MILLION)
TABLE 120 MEXICO: GUT MICROBIOME TESTING, BY INDICATION, 2019–2036 (USD MILLION)
TABLE 121 MEXICO: GUT MICROBIOME TESTING, BY END USER, 2019–2036 (USD MILLION)
TABLE 122 ARGENTINA: GUT MICROBIOME TESTING, BY PRODUCT & SERVICE, 2019–2036 (USD MILLION)
TABLE 123 ARGENTINA: GUT MICROBIOME TESTING, BY APPLICATION, 2019–2036 (USD MILLION)
TABLE 124 ARGENTINA: GUT MICROBIOME TESTING, BY SAMPLE TYPE, 2019–2036 (USD MILLION)
TABLE 125 ARGENTINA: GUT MICROBIOME TESTING, BY INDICATION, 2019–2036 (USD MILLION)
TABLE 126 ARGENTINA: GUT MICROBIOME TESTING, BY END USER, 2019–2036 (USD MILLION)
TABLE 127 REST OF SOUTH AMERICA: GUT MICROBIOME TESTING, BY PRODUCT & SERVICE, 2019–2036 (USD MILLION)
TABLE 128 REST OF SOUTH AMERICA: GUT MICROBIOME TESTING, BY APPLICATION, 2019–2036 (USD MILLION)
TABLE 129 REST OF SOUTH AMERICA: GUT MICROBIOME TESTING, BY SAMPLE TYPE, 2019–2036 (USD MILLION)
TABLE 130 REST OF SOUTH AMERICA: GUT MICROBIOME TESTING, BY INDICATION, 2019–2036 (USD MILLION)
TABLE 131 REST OF SOUTH AMERICA: GUT MICROBIOME TESTING, BY END USER, 2019–2036 (USD MILLION)
TABLE 132 MIDDLE EAST & AFRICA: GUT MICROBIOME TESTING, BY COUNTRY, 2019-2035 (USD MILLION)
TABLE 133 MIDDLE EAST & AFRICA: GUT MICROBIOME TESTING, BY PRODUCT & SERVICE, 2019–2036 (USD MILLION)
TABLE 134 MIDDLE EAST & AFRICA: GUT MICROBIOME TESTING, BY APPLICATION, 2019–2036 (USD MILLION)
TABLE 135 MIDDLE EAST & AFRICA: GUT MICROBIOME TESTING, BY SAMPLE TYPE, 2019–2036 (USD MILLION)
TABLE 136 MIDDLE EAST & AFRICA: GUT MICROBIOME TESTING, BY INDICATION, 2019–2036 (USD MILLION)
TABLE 137 MIDDLE EAST & AFRICA: GUT MICROBIOME TESTING, BY END USER, 2019–2036 (USD MILLION)
TABLE 138 GCC COUNTRIES: GUT MICROBIOME TESTING, BY PRODUCT & SERVICE, 2019–2036 (USD MILLION)
TABLE 139 GCC COUNTRIES: GUT MICROBIOME TESTING, BY APPLICATION, 2019–2036 (USD MILLION)
TABLE 140 GCC COUNTRIES: GUT MICROBIOME TESTING, BY SAMPLE TYPE, 2019–2036 (USD MILLION)
TABLE 141 GCC COUNTRIES: GUT MICROBIOME TESTING, BY INDICATION, 2019–2036 (USD MILLION)
TABLE 142 GCC COUNTRIES: GUT MICROBIOME TESTING, BY END USER, 2019–2036 (USD MILLION)
TABLE 143 SOUTH AFRICA: GUT MICROBIOME TESTING, BY PRODUCT & SERVICE, 2019–2036 (USD MILLION)
TABLE 144 SOUTH AFRICA: GUT MICROBIOME TESTING, BY APPLICATION, 2019–2036 (USD MILLION)
TABLE 145 SOUTH AFRICA: GUT MICROBIOME TESTING, BY SAMPLE TYPE, 2019–2036 (USD MILLION)
TABLE 146 SOUTH AFRICA: GUT MICROBIOME TESTING, BY INDICATION, 2019–2036 (USD MILLION)
TABLE 147 SOUTH AFRICA: GUT MICROBIOME TESTING, BY END USER, 2019–2036 (USD MILLION)
TABLE 148 REST OF MIDDLE EAST & AFRICA: GUT MICROBIOME TESTING, BY PRODUCT & SERVICE, 2019–2036 (USD MILLION)
TABLE 149 REST OF MIDDLE EAST & AFRICA: GUT MICROBIOME TESTING, BY APPLICATION, 2019–2036 (USD MILLION)
TABLE 150 REST OF MIDDLE EAST & AFRICA: GUT MICROBIOME TESTING, BY SAMPLE TYPE, 2019–2036 (USD MILLION)
TABLE 151 REST OF MIDDLE EAST & AFRICA: GUT MICROBIOME TESTING, BY INDICATION, 2019–2036 (USD MILLION)
TABLE 152 REST OF MIDDLE EAST & AFRICA: GUT MICROBIOME TESTING, BY END USER, 2019–2036 (USD MILLION)
TABLE 153 INDUSTRY KEY DEVELOPMENT
TABLE 154 VIOME, INC.: PRODUCTS OFFERED
TABLE 155 OMBRE: PRODUCTS OFFERED
TABLE 156 BASECLEAR B.V: PRODUCTS OFFERED
TABLE 157 ATLAS BIOLABS: PRODUCTS OFFERED
TABLE 158 MICROBA LIFE SCIENCES.: PRODUCTS OFFERED
TABLE 159 GENOVA DIAGNOSTICS, INC.: PRODUCTS OFFERED
TABLE 160 SUN GENOMICS INC.: PRODUCTS OFFERED
TABLE 161 BIOHM HEALTH INC.: PRODUCTS OFFERED
TABLE 162 ZYMO RESEARCH CORPORATION: PRODUCTS OFFERED
TABLE 163 COSMOSID INC.: PRODUCTS OFFERED